valproic acid has been researched along with Diffuse Large B-Cell Lymphoma in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to illustrate the mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by histone deacetylase inhibitor valproic acid (VPA) combined with mTOR inhibitor temsirolimus (TEM)." | 7.79 | [Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus]. ( Cheng, S; Dong, LH; Wang, L; Zhao, WL; Zhao, Y; Zheng, Z, 2013) |
| "The aim of this study was to illustrate the mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by histone deacetylase inhibitor valproic acid (VPA) combined with mTOR inhibitor temsirolimus (TEM)." | 3.79 | [Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus]. ( Cheng, S; Dong, LH; Wang, L; Zhao, WL; Zhao, Y; Zheng, Z, 2013) |
| " Treatment was commenced with the HDACi sodium valproate (VPA) in combination with the anti-viral nucleoside analogue ganciclovir (GCV)." | 1.36 | Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. ( Corbett, G; Gandhi, MK; Jones, K; Nourse, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drott, K | 1 |
| Hagberg, H | 1 |
| Papworth, K | 1 |
| Relander, T | 1 |
| Jerkeman, M | 1 |
| Zheng, Z | 1 |
| Zhao, Y | 1 |
| Dong, LH | 1 |
| Wang, L | 1 |
| Cheng, S | 1 |
| Zhao, WL | 1 |
| Jones, K | 1 |
| Nourse, J | 1 |
| Corbett, G | 1 |
| Gandhi, MK | 1 |
| Ivanova, D | 1 |
| Gronemeyer, H | 1 |
| Steinberg, P | 1 |
| Nau, H | 1 |
| Zain, J | 1 |
| Rotter, A | 1 |
| Weiss, L | 1 |
| Forman, S | 1 |
| Kirschbaum, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma[NCT01622439] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for valproic acid and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Histone | 2018 |
4 other studies available for valproic acid and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Topics: Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Histon | 2013 |
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity.
Topics: Antiviral Agents; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Histone Deacetylase Inh | 2010 |
Enantioselective apoptosis induction in histiocytic lymphoma cells and acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Flow Cytometry; Histone Deacetylase Inhibitors | 2013 |
Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, | 2007 |